Kairos PharmaKAPA
13F holders, Q3 2025 (September 30)14holders +4
6new positions
2sold out
$1.14avg. 13F price*
At the end of Q3 2025, 14 institutions reported holding Kairos Pharma Ltd. (KAPA) in their 13F filings, up 4 from Q2 2025. 6 opened new positions and 2 sold out. The largest holders were Vanguard Group Inc. ($154K), Geode Capital Management, LLC ($77K) and Two Sigma Investments, LP ($54K).
- Company
- Kairos Pharma Ltd.
- CUSIP
- 48301N104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $281K |
| Exits | 2 | $13K |
All 13F filers, Q2 2025 → Q3 2025: 298,853 shares bought and 72,555 shares sold, net +226,298 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| Vanguard Group Inc. | 0.00% | New | 131,828 | $154K |
| Geode Capital Management, LLC | 0.00% | Add +201.8% | 65,800 | $77K |
| Two Sigma Investments, LP | 0.00% | New | 45,789 | $54K |
| Aptus Capital Advisors, LLC | 0.00% | No change | 44,286 | $52K |
| SevenBridge Financial Group, LLC | 0.01% | No change | 44,286 | $38K |
| Two Sigma Securities, LLC | 0.00% | Add +83.7% | 24,895 | $29K |
| State Street Corp. | 0.00% | New | 24,100 | $28K |
| FNY Investment Advisers, LLC | 0.01% | New | 23,500 | $27K |
| Quadrature Capital Ltd | 0.00% | New | 14,887 | $17K |
| XTX Topco Ltd | 0.00% | Reduce -80.2% | 12,408 | $15K |
| UBS Group AG | 0.00% | Reduce -36.8% | 5,979 | $7K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +56.9% | 5,957 | $7K |
| Royal Bank of Canada | 0.00% | New | 1,000 | $1K |
| Bank of America Corp. | 0.00% | Add +496.1% | 304 | $356 |
"% of holder's portfolio" is KAPA's weight in each manager's 13F, not the share of Kairos Pharma Ltd. the manager owns.